PASG News and Press, Passage Bio Inc. From 01/22/21

Senseonics Holdings (SENS) -16% after raising size of stock offering.Global Ship Lease (GSL) -14% after announcing public offering.Globalstar (GSAT) -13% after Morgan Stanley cuts to underweight on valuation.Broadwind (BWEN) -13% after guiding Q4 revenu...

Passage Bio (PASG) has priced its public offering of 7M common shares at $22.00/share, for expected gross proceeds of $154M.Underwriters' over-allotment is an additional 1.05M shares.Closing date is January 26.Previously (Jan. 19): Passage Bio announces launch of proposed public offering of 7...

PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced the pricing of its underwritten public offering of 7,000,000 shar...

Genetic medicines company Passage Bio (PASG) announces that it has commenced an underwritten public offering of 7M shares of its common stock.Passage Bio intends to grant the underwriters a 30-day option to purchase up to an additional 1.05M shares at the public offering price, less unde...

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced that it has commenced an underwritten public offering of 7,000,00...

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Development even...

– Investigational New Drug Applications (IND) submitted for PBFT02 for Frontotemporal Dementia with Granulin Mutation (FTD-GRN) and PBKR03 for Krabbe Disease – – Three clinical programs to begin in 1H21 – – Metachromatic leukodystroph...

PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive offic...

The FDA has signed off investigational new drug ((IND)) application for Passage Bio's (PASG) lead product candidate, PBGM01, an adeno-associated virus-delivery gene therapy that is being studied for the treatment of infantile GM1 gangliosidosisDosing in Imagine-1 Phase 1/2...

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021 PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on...